Benzinga

Benzinga

Benzinga

mercoledì, settembre 02

HCA Healthcare Inc

HCANYSE
Trade with Public
Trade with Public
$413.58
-0.87-0.21%
In chiusura: Aug 31, 5:00 PM EST
$410.65
-3.80-0.92%
Pre-mercato: 7:14 AM EST
Dividendo: La data di stacco del dividendo è tra 14 giorni
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

HCA Healthcare Analyst Price Targets

Wall Street analyst price targets and consensus rating for HCA Healthcare (HCA).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

13Buy
6Hold
1Sell
Consensus RatingBuy# Analysts20Avg. Consensus PT$470Upside to Avg. PT+14.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 20, 2026JP MorganBenjamin RossiPT CutNeutral$490→$425
Aug 3, 2026Wells FargoStephen BaxterPT RaiseEqual-Weight$369→$381
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Neutral on HCA Healthcare, Lowers Price Target to $425

JP Morgan analyst Benjamin Rossi maintains HCA Healthcare (NYSE:HCA) with a Neutral and lowers the price target from $490 to $425.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $381

Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:HCA) with a Equal-Weight and raises the price target from $369 to $381.
Benzinga Newsdesk

PRO
Goldman Sachs Maintains Buy on HCA Healthcare, Lowers Price Target to $485

Goldman Sachs analyst Scott Fidel maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $558 to $485.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on HCA Healthcare, Lowers Price Target to $475

Mizuho analyst Ann Hynes maintains HCA Healthcare (NYSE:HCA) with a Outperform and lowers the price target from $525 to $475.
Benzinga Newsdesk

PRO
UBS Maintains Buy on HCA Healthcare, Lowers Price Target to $579

UBS analyst A.J. Rice maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $635 to $579.
Benzinga Newsdesk

Behind HCA's Q2 Beat: One-Time Medicaid Boost and a Growing Insurance Headwind

HCA's Q2 results beat expectations. Company resets 2026 guidance on HIX headwinds and decline in surgeries.
Priya Nigam

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved